Clinical Trial Update: A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy [Phase 2]

View source ↗

Summary

The Phase 2 study of ATL1102 vs placebo in non-ambulatory Duchenne Muscular Dystrophy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• ATL1102

Snippet

Sponsor: Percheron Therapeutics | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: TERMINATED